Alzinova AB
78D
Company Profile
Business description
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is developing ALZ-101, an oligomer-specific therapeutic vaccine currently advancing toward Phase 2 clinical development, and ALZ-201, a monoclonal antibody targeting toxic amyloid-beta (AB) oligomers, which is in preclinical development. The company's proprietary ABCC peptide technology is focused on disease-modifying treatments for Alzheimer's disease.
Contact
Entreprenorsstraket 10
GoCo House
Molndal431 53
SWESector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
ASX top pick remains cheap despite weaker consumer confidence
Consumer caution dents growth, shares look cheap.
stocks
Chart of the Week: Aussie dividend yields below 10-year average
Income opportunities remain beneath the surface.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,112.90 | 92.30 | -1.00% |
| CAC 40 | 8,205.37 | 27.48 | 0.34% |
| DAX 40 | 26,325.01 | 112.66 | -0.43% |
| Dow JONES (US) | 51,523.06 | 1,833.06 | -3.44% |
| FTSE 100 | 10,782.66 | 46.55 | -0.43% |
| HKSE | 24,533.33 | 263.65 | -1.06% |
| NASDAQ | 24,315.00 | 1,421.52 | -5.52% |
| Nikkei 225 | 57,296.33 | 3,781.57 | -6.19% |
| NZX 50 Index | 13,998.50 | 92.47 | -0.66% |
| S&P 500 | 7,353.73 | 334.89 | -4.36% |
| S&P/ASX 200 | 8,987.30 | 77.80 | -0.86% |
| SSE Composite Index | 3,647.90 | 42.01 | -1.14% |